Clinical Trials

Inclusion Criteria:

• Women ≥ 35 years old and ≤ 75 years old.
• Women that meet at least one of the following:
  • NCI-BCRAT 5-year risk (> 3%) or that shows at least moderate evidence of treatment benefit outweighing risk according to the US Preventative Services Task Force or IBIS (version 8) risk calculator (> 8% for the 10-year risk);
  • History of atypical hyperplasia (30% lifetime risk for developing breast cancer);
  • LCIS (approximately 20% lifetime risk for developing breast cancer);
  • Status post-surgery (lumpectomy or unilateral mastectomy) for ER positive DCIS;
  • Status post-surgery (lumpectomy or unilateral mastectomy) for pleomorphic LCIS.

Exclusion Criteria:

• Women whose BCRAT falls below the threshold moderate according to the US Preventative Task Force or IBIS (version 8) 10 year risk of < 8%; OR do not have a surgical finding that demonstrates increased risk of developing invasive breast cancer.
• Women with known BRCA1 and BRCA2 mutations.
• Women with known contraindications to tamoxifen, raloxifene, exemestane or anastrozole.
• Women unable to give informed consent.
• Prior history of invasive breast cancer.
• At-risk women due to prior radiation therapy to the chest.
• Prior use of preventive medications (tamoxifen, raloxifene, exemestane or anastrozole) for breast cancer prevention.